Retatrutide vs Tirzepatide: Research Peptide Comparison

Retatrutide and tirzepatide are both engineered metabolic research peptides that have generated wide research interest. This comparison summarises how each compound is described in published literature, how Amino Fuel Labs documents lot quality, and the practical considerations researchers raise when sourcing either compound. Everything below is research peptide information for laboratory research only.

Receptor pharmacology side by side

Tirzepatide is described in literature as a dual GLP-1 and GIP receptor agonist. Retatrutide is described as a triple agonist that adds glucagon receptor activity to the GLP-1 / GIP profile. Investigators studying multi-incretin signalling therefore frequently reference both peptides in the same paper. We make no human-use claims and provide no therapeutic guidance for either compound.

Reported research dose ranges

Published research and clinical trial summaries describe both compounds at sub-milligram weekly ranges, with dose ranges varying by study design and receptor target. Investigators design their own protocols based on the model and reference literature. Amino Fuel Labs does not publish human dosing recommendations.

Lot documentation, identity, and purity

Each lot of retatrutide and tirzepatide is verified by reverse-phase HPLC at a third-party analytical lab. The COA documents identity, appearance, lot number, manufacture and retest dates, and HPLC purity. Researchers receive a vial whose label matches the COA, supporting reproducible documentation across studies.

Selecting between them in research

Tirzepatide is typically chosen when a researcher wants a defined dual-receptor profile; retatrutide is typically chosen when triple-agonist pharmacology is in scope. Both ship lyophilized, with cold-chain-aware packaging, for laboratory research only. Products are not for human consumption and are not intended to treat, cure, diagnose, heal, or prevent any disease.